CFO
IONS icon

Callan Family Office’s Ionis Pharmaceuticals IONS Stock Holding History

Callan Family Office’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$566K Buy
7,143
+61
+0.9% +$4.59K 0.01% 776
2026
Q1 		$532K Sell
7,082
-22
-0.3% -$1.74K 0.01% 744
2025
Q4 		$562K Buy
+7,104
New +$535K 0.01% 746
2025
Q3 		– Sell
-5,400
Closed -$213K – 900
2025
Q2 		$213K Buy
+5,400
New +$177K 0.01% 880

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Callan Family Office's IONS Position: Q2 2026 in Review

Callan Family Office increased its Ionis Pharmaceuticals (IONS) stake by 0.86% in Q2 2026, buying an estimated $4.59K and bringing the position to 7,143 shares worth $566K. The position accounts for 0.01% of the portfolio, ranked #776.

Callan Family Office first reported a position in IONS in Q2 2025 and has held it in 4 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Callan Family Office held 7,143 shares of Ionis Pharmaceuticals worth $566K as of Q2 2026.
  • Callan Family Office bought 61 Ionis Pharmaceuticals shares in Q2 2026, an estimated $4.59K.
  • Ionis Pharmaceuticals made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #776 holding.
  • Callan Family Office first reported a position in Ionis Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.